Human pluripotent stem cells - including those used in human clinical trials - recurrently acquire and expand dominant negative P53 mutations, a type of mutation associated with a large increased risk of cancer.

See the source article by following the link below:
Human pluripotent stem cells - including those used in human clinical trials - recurrently acquire and expand dominant negative P53 mutations, a type of mutation associated with a large increased risk of cancer.